<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">626272</article-id><article-id pub-id-type="doi">10.26442/20751753.2023.10.202164</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Tumor necrosis factor gene polymorphism rs1800629 in patients with atherosclerotic cardiovascular diseases: A review</article-title><trans-title-group xml:lang="ru"><trans-title>Полиморфизм гена фактора некроза опухоли rs1800629 у пациентов с атеросклеротическими сердечно-сосудистыми заболеваниями: обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8050-2892</contrib-id><name-alternatives><name xml:lang="en"><surname>Khazova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Хазова</surname><given-names>Елена Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. пропедевтики внутренних болезней им. проф. С.С. Зимницкого</p></bio><email>hazova_elena@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7228-5848</contrib-id><name-alternatives><name xml:lang="en"><surname>Bulashova</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Булашова</surname><given-names>Ольга Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., проф. каф. пропедевтики внутренних болезней им. проф. С.С. Зимницкого</p></bio><email>boulashova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7080-3878</contrib-id><name-alternatives><name xml:lang="en"><surname>Valeeva</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Валеева</surname><given-names>Елена Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Bio.),Res.</p></bio><bio xml:lang="ru"><p>канд. биол. наук, стар. науч. сотр. центральной научно-исследовательской лаб.</p></bio><email>vevaleeva@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kazan State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2023</year></pub-date><volume>25</volume><issue>10</issue><issue-title xml:lang="en">Cardiovascular diseases</issue-title><issue-title xml:lang="ru">Болезни сердца и сосудов</issue-title><fpage>674</fpage><lpage>678</lpage><history><date date-type="received" iso-8601-date="2024-01-30"><day>30</day><month>01</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-01-30"><day>30</day><month>01</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/626272">https://consilium.orscience.ru/2075-1753/article/view/626272</self-uri><abstract xml:lang="en"><p>The close attention of researchers is riveted to the study of socially significant multifactorial diseases and syndromes with a hereditary predisposition, which include chronic heart failure, formed as a result of atherosclerosis of the coronary arteries. The promise of genomic studies in atherosclerosis and heart failure is associated with the possibility of determining the genetic risk of developing and predicting adverse cardiovascular events before the onset of clinical signs/symptoms. From the standpoint of understanding the pathogenesis of atherosclerosis as a variant of nonspecific inflammation, which has a wave-like character, it is assumed that genes encoding pro-inflammatory cytokines influence the pathological process. The aim of the review was to analyze the results of studies available in available publications on the rs1800629 polymorphism of the tumor necrosis factor (<italic>TNF</italic>) gene in patients with atherosclerotic cardiovascular diseases. Most data indicate the presence of an increased cardiovascular risk in carriers of the A allele of the rs1800629 polymorphism of the <italic>TNF</italic> gene. It was determined that carriage of the AA genotype is associated with essential arterial hypertension and remodeling of the left ventricular myocardium. In patients with chronic heart failure with preserved and moderately reduced left ventricular ejection fraction of the AA genotype, low blood pressure and frequent occurrence of atrial fibrillation were noted. A number of papers present the results of studies of the rs1800629 polymorphism of the <italic>TNF </italic>gene and the prognostic significance of the rs1800629 polymorphism of the <italic>TNF</italic> gene in heart failure.</p></abstract><trans-abstract xml:lang="ru"><p>Пристальное внимание исследователей приковано к изучению социально значимых многофакторных заболеваний и синдромов с наследственной предрасположенностью, к которым относится и хроническая сердечная недостаточность (СН), сформировавшаяся вследствие атеросклероза (АС) коронарных артерий. Перспективность геномных исследований при АС и СН связывают с возможностью определения генетического риска развития и прогноза нежелательных сердечно-сосудистых событий до появления клинических признаков/симптомов. С позиции понимания патогенеза АС как варианта неспецифического воспаления, имеющего волнообразный характер, предполагается влияние на патологический процесс генов, кодирующих провоспалительные цитокины. Целью обзора был анализ результатов исследований, имеющихся в доступных публикациях, полиморфизма rs1800629 гена фактора некроза опухоли (tumor necrosis factor – <italic>TNF</italic>) у пациентов с атеросклеротическими сердечно-сосудистыми заболеваниями. Большинство данных свидетельствуют о наличии повышенного сердечно-сосудистого риска у носителей аллеля А полиморфизма rs1800629 гена<italic> TNF</italic>. Определено, что носительство генотипа АА ассоциировано с эссенциальной артериальной гипертензией и ремоделированием миокарда левого желудочка. У пациентов с хронической СН с сохраненной и умеренно-сниженной фракцией выброса левого желудочка АА-генотипа отмечены низкие показатели артериального давления и частая встречаемость фибрилляции предсердий. В ряде работ приведены результаты исследований полиморфизма rs1800629 гена <italic>TNF</italic>, продемонстрирована его прогностическая значимость при СН.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rs1800629 polymorphism</kwd><kwd>TNF gene</kwd><kwd>TNF-α</kwd><kwd>atherosclerotic cardiovascular diseases</kwd><kwd>chronic heart failure</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>полиморфизм rs1800629</kwd><kwd>ген TNF</kwd><kwd>фактор некроза опухоли α</kwd><kwd>атеросклеротические сердечно-сосудистые заболевания</kwd><kwd>хроническая сердечная недостаточность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Guo M, Guo G, Ji X. Genetic polymorphisms associated with heart failure: A literature review. J Int Med Res. 2016;44(1):15-29. DOI:10.1177/0300060515604755</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Хазова Е.В., Булашова О.В., Ослопов В.Н., и др. Фактор некроза опухоли α – маркер системного воспаления у пациентов с сердечной недостаточностью. Практическая медицина. 2017;2(103):24-7 [Khazova EV, Bulashova OV, Oslopov VN, et al. Tumor necrosis factor α – a marker of systemic inflammation in patients with heart failure. Practical Medicine. 2017;2(103):24-7 (in Russian)].</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cho H-Ch, Yu G, Lee M-Yu, et al. TNF-α polymorphism and coronary artery disease; association study in the Korean population. Cytokine. 2013;62(1):104-9. DOI:10.1016/j.cyto.2013.02.008</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kumari R, Kumar S, Ahmad MK, et al. Promoter variants of TNF-α rs1800629 and IL-10 rs1800871 are independently associated with the susceptibility of coronary artery disease in north Indian. Cytokine. 2018;110:131-6. DOI:10.1016/j.cyto.2018.04.035</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mishra A, Srivastava A, Mittal T, et al. Role of inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease patients. Cytokine. 2013;61(3):856-61. DOI:10.1016/j.cyto.2012.12.020</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tian M, Yuan Yu-Ch, Li J-Y, et al. Tumor necrosis factor-α and its role as a mediator in myocardial infarction: A brief review. Chronic Dis Transl Med. 2015;1(1):18-26. DOI:10.1016/j.cdtm.2015.02.002</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Schumacher SM, Naga Prasad SV. Tumor necrosis factor-α in heart failure: An updated review. Curr Cardiol Rep. 2018;20(11):117. DOI:10.1007/s11886-018-1067-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Flesch M, Höper A, Dell'Italia L, et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003;108(5):598-604. DOI:10.1161/01.CIR.0000081768.13378.BF</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Tromp J, Khan MA, Klip UT, et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc. 2017;6(4):e003989. DOI:10.1161/JAHA.116.003989</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hua XP, Qian J, Cao CB, et al. Association between the TNF-α rs1800629 polymorphism and the risk of myocardial infarction: A meta-analysis. Genet Mol Res. 2016;15(3):gmr.15037292. DOI:10.4238/gmr.15037292</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Pulido-Gómez K, Hernández-Díaz Y, Tovilla-Zárate CA, et al. Association of G308A and G238A polymorphisms of the TNF-α gene with risk of coronary heart disease: Systemic review and meta-analysis. Arch Med Res. 2016;47(7):557-72. DOI:10.1016/j. arcmed.2016.11.006</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>rs1800629 SNP. Available at: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;v=rs1800629;vdb=variation. Accessed: 25.03.2023.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94(7):3195-9. DOI:10.1073/pnas.94.7.3195</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Li Y, Chunjiang F, Xukai W, Chunyu Z. A meta analysis of the relation between TNF-α G308A gene polymorphism and heart disease. Life Sci J. 2014;11(4):204-6.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kabita S, Garg PR, Newmei MK, et al. Tumor necrosis factor-alpha gene polymorphisms and complex disorders: A study among mendelian population with East Asian Ancestry. J Pract Cardiovasc Sci. 2019;5(1):35-43. DOI:10.4103/jpcs.jpcs_6_19</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Гараева Л.А., Маянская С.Д. Ассоциация полиморфных локусов генов провоспалительных цитокинов у пациентов с коронарным и периферическим атеросклерозом различной степени тяжести. Международный научно-исследовательский журнал. 2017;1-1(55):102-6 [Garaeva LA, Mayanskaya SD. Association of polymorphic loci of pro-inflammatory cytokine genes in patients with coronary and peripheral atherosclerosis of varying severity. International Research Journal. 2017;1-1(55):102-6 (in Russian)]. DOI:10.23670/IRJ.2017.55.087</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Шумилов Д.С., Тугуз А.Р., Смольков И.В., и др. Полиморфизмы генов основных про- и противовоспалительных цитокинов: IL-1 (T511C, RS16944), TNF-α (G308A, RS1800629), IL-4 (C589T, RS2243250) при коронарном атеросклерозе. Вестник Адыгейского государственного университета. Серия 4: Естественно-математические и технические науки. 2017;1(196):41-6 [Shumilov DS, Tuguz AR, Smolkov IV, et al. Gene polymorphisms of major pro- and anti-inflammatory cytokines: IL-1 (T511C, RS16944), TNF-α (G308A, RS1800629), IL-4 (C589T, RS2243250) in coronary atherosclerosis. Bulletin of the Adyghe State University. Series 4: Natural-mathematical and Technical Sciences. 2017;1(196):41-6 (in Russian)].</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fawzy RM, Hammad GA, Egila SE, et al. Association of tumor necrosis factor-α (TNF-α) -308A/G (rs1800629) gene polymorphism with carotid artery atherosclerosis in rheumatoid arthritis patients. The Egyptian Rheumatologist. 2020;40(3):177-81. DOI:10.1016/j.ejr.2020.05.004</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Rodríguez-Rodríguez L, González-Juanatey C, Palomino-Morales R, et al. TNFα-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis. 2011;216(1):125-30. DOI:10.1016/j.atherosclerosis.2010.10.052</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Wang W, Peng WH, Lu L, et al. Polymorphism on chromosome 9p21.3 contributes to early onset and severity of coronary artery disease in non-diabetic and type 2 diabetic patients. Chin Med J (Engl). 2011;124(1):66-71. DOI:10.3901/jme.2011.08.066</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Chu H, Yang J, Mi S, et al. Tumor necrosis factor-alpha G-308 A polymorphism and risk of coronary heart disease and myocardial infarction: A case-control study and meta-analysis. J Cardiovasc Dis Res. 2012;3(2):84-90. DOI:10.4103/0975-3583.95359</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Hussain S, Iqbal T, Javed Q. TNF-alpha-308G&gt;A polymorphism and the risk of familial CAD in a Pakistani population. Hum Immunol. 2015;76(1):13-8. DOI:10.1016/j.humimm.2014.12.010</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mastana S, Prakash S, Akam EC, et al. Genetic association of proinflammatory cytokine gene polymorphisms with coronary artery disease (CAD) in a North Indian population. Gene. 2017;628:301-7. DOI:10.1016/j.gene.2017.07.050</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Khan NS, Shaheen N, Sultan AM, et al. Genetic association of tumour necrosis factor alpha, interleukin-18 and Interleukin 1 beta with the risk of coronary artery disease: A case-control study outcome from Kashmir. J Appl Biomed. 2018;16:387-93. DOI:10.1016/j.jab.2018.02.004</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Parham N, Samaneh N, Aref S, Majid S. Association of tumor necrosis factor-alpha gene promoter polymorphism and its mRNA expression level in coronary artery disease. Meta Gene. 2018;18:122-6. DOI:10.1016/j.mgene.2018.08.009</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Pan J, Hu J, Qi X, Xu L. Association study of a functional variant of TNF-α gene and serum TNF-α level with the susceptibility of congenital heart disease in a Chinese population. Postgrad Med J. 2019;95(1128):547-51. DOI:10.1136/postgradmedj-2019-136621</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Abdulfattah SY, Samawi FT. Estimating the role of single-nucleotide polymorphism (rs1800629)-308 G/A of TNF-alpha gene as genetic marker associated with angina pectoris in a sample of Iraqi patients. J Genet Eng Biotechnol. 2023;21(1):2. DOI:10.1186/s43141-022-00454-w</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Huang R, Zhao SR, Li Y, et al. Association of tumor necrosis factor-α gene polymorphisms and coronary artery disease susceptibility: A systematic review and meta-analysis. BMC Med Genet. 2020;21(1):29. DOI:10.1186/s12881-020-0952-2</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Zeybek U, Toptas B, Karaali ZE, et al. Effect of TNF-α and IL-1β genetic variants on the development of myocardial infarction in Turkish population. Mol Biol Rep. 2011;38(8):5453-7. DOI:10.1007/s11033-011-0701-x</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Biswas S, Ghoshal PK, Mandal N. Synergistic effect of anti and pro-inflammatory cytokine genes and their promoter polymorphism with ST-elevation of myocardial infarction. Gene. 2014;544(2):145-51. DOI:10.1016/j.gene.2014.04.065</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Зыков М.В., Макеева О.А., Голубенко М.В., и др. Исследование полиморфизма rs1800629 (G-308A) гена TNF больных инфарктом миокарда с подъемом сегмента ST. Российский кардиологический журнал. 2014;19(10):13-8 [Zykov MV, Makeeva OA, Golubenko MV, et al. Study of the rs1800629 (G-308A) polymorphism of the TNF gene in patients with ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2014;19(10):13-8 (in Russian)]. DOI:10.15829/1560-4071-2014-10-13-18</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Аймагамбетова А.О., Каражанова Л.К., Котляр А. Полиморфизм генов цитокинов при инфаркте миокарда с подъемом сегмента ST у лиц казахской национальности. Вестник Казахского национального медицинского университета. 2017;4:417-21 [Aimagambetova AO, Karazhanova LK, Kotlyar A. Cytokine gene polymorphism with myocardial infarction with elevated ST-segment in subjects of Kazakh nationality. Bulletin of the Kazakh National Medical University. 2017;4:417-21 (in Russian)].</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Маянская С.Д., Гараева Л.А., Тепляков А.Т., и др. Особенности полиморфизма генов FGB, TNFα, IL-1β, LPL, ITGB3 и TGFB1 у пациентов с повторным инфарктом миокарда. Бюллетень сибирской медицины. 2020;19(4):130-7 [Mayanskaya SD, Garaeva LA, Teplyakov AT, et al. FGB, TNFα, IL-1β, LPL, ITGB3, and TGFB1 gene polymorphism features in patients with recurrent myocardial infarction. Bulletin of Siberian Medicine. 2020;19(4):130-7 (in Russian)]. DOI:10.20538/1682-0363-2020-4-130-137</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Шишкина Е.А., Агафонов А.В., Хлынова О.В., Кривцов А.В. Взаимосвязь полиморфизма G-308A гена TNF с риском развития инфаркта миокарда у больных трудоспособного возраста. Уральский медицинский журнал. 2020;10(193):109-15 [Shishkina EA, Agafonov AV, Khlynova OV, Krivtsov AV. Correlation of G-308A polymorphism of the TNF gene with the risk of myocardial infarction in patients of working age. Ural Medical Journal. 2020;10(193):109-15 (in Russian)]. DOI:10.25694/URMJ.2020.10.42</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Grira N, Lahidheb D, Lamine O, et al. The association of IL-6, TNFα and CRP gene polymorphisms with coronary artery disease in a Tunisian population: A case-control study. Biochem Genet. 2021;59(3):751-66. DOI:10.1007/s10528-021-10035-0</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Пушкарева А.Э., Арутюнов Г.П., Хусаинова Р.И., Хуснутдинова Э.К. Исследование полиморфных вариантов генов цитокинов (TNFα, TNFβ) и гена метилентетрагидрофолатредуктазы (MTHFR) при различных типах ремоделирования сердца. Медицинский вестник Башкортостана. 2012;7(4):40-4 [Pushkareva AE, Arutyunov GP, Khusainova RI, Khusnutdinova EK. The analysis of polymorphic variants of cytokines genes (TNFα, TNFβ) and methylentetrahydrofoloatreductase (MTHFR) gene in heart failure patients with different types of heart remodelling. Medical Bulletin of Bashkortostan. 2012;7(4):40-4 (in Russian)].</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Bielecka-Dabrowa A, Sakowicz A, Pietrucha T, et al. The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. Sci Rep. 2017;7(1):8974. DOI:10.1038/s41598-017-09564-9</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Тепляков А.Т., Шилов С.Н., Попова А.А., и др. Роль провоспалительных цитокинов в развитии антрациклин-индуцированной сердечной недостаточности. Сибирский медицинский журнал. 2020;35(2):66-74 [Teplyakov AT, Shilov SN, Popova AA, et al. The role of proinflammatory cytokines in the development of anthracycline-induced heart failure. The Siberian Journal of Clinical and Experimental Medicine. 2020;35(2):66-74 (in Russian)]. DOI:10.29001/2073-8552-2020-35-2-66-74</mixed-citation></ref></ref-list></back></article>
